Success Metrics

Clinical Success Rate
61.5%

Based on 8 completed trials

Completion Rate
62%(8/13)
Active Trials
0(0%)
Results Posted
13%(1 trials)
Terminated
5(38%)

Phase Distribution

Ph phase_2
9
69%
Ph phase_3
1
8%
Ph phase_1
3
23%

Phase Distribution

3

Early Stage

9

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
9(69.2%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

61.5%

8 of 13 finished

Non-Completion Rate

38.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(8)
Terminated(5)

Detailed Status

Completed8
Terminated5

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
61.5%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (23.1%)
Phase 29 (69.2%)
Phase 31 (7.7%)

Trials by Status

terminated538%
completed862%

Recent Activity

0 active trials
Showing 5 of 13
terminatedphase_2

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

NCT00084487
completedphase_2

Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

NCT00003737
completedphase_2

Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer

NCT00005027
completedphase_1

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

NCT00004189
completedphase_2

Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

NCT00005085
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00084487Phase 2

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

Terminated
NCT00003737Phase 2

Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

Completed
NCT00005027Phase 2

Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer

Completed
NCT00004189Phase 1

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

Completed
NCT00005085Phase 2

Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Completed
NCT00006102Phase 2

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

Completed
NCT00005817Phase 2

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

Completed
NCT00087204Phase 1

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Completed
NCT00086983Phase 1

Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

Terminated
NCT00006262Phase 2

Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer

Terminated
NCT00005997Phase 2

Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer

Terminated
NCT00006017Phase 2

Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Completed
NCT00090025Phase 3

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Terminated

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13